Yesterday, May 26, 2016, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $0.02 to $20,083,643.73.

Highlighted Stocks Traded by Insiders:

Amphastar Pharmaceuticals (AMPH) - FREE Research Report

Shandell Jason B., who is President at Amphastar Pharmaceuticals, sold 1,074 shares at $15.60 on May 26, 2016. Following this transaction, the President owned 226,514 shares meaning that the stake was reduced by 0.47% with the 1,074-share transaction.

The shares most recently traded at $15.82, up $0.22, or 1.39% since the insider transaction. Historical insider transactions for Amphastar Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,627
  • 12-Week # shares sold: 8,454
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 9,226

The average volume for Amphastar Pharmaceuticals has been 231,700 shares per day over the past 30 days. Amphastar Pharmaceuticals has a market cap of $694.7 million and is part of the health care sector and drugs industry. Shares are up 8.57% year-to-date as of the close of trading on Thursday.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has a P/E ratio of 1548.0. Currently, there are 5 analysts who rate Amphastar Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMPH - FREE

TheStreet Quant Ratings rates Amphastar Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a decline in price during the past year. Get the full Amphastar Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

iPass (IPAS) - FREE Research Report

Morrison Brent, who is Director at iPass, sold 9,100 shares at $1.16 on May 26, 2016. Following this transaction, the Director owned 17,200 shares meaning that the stake was reduced by 34.6% with the 9,100-share transaction.

The shares most recently traded at $1.30, up $0.14, or 10.77% since the insider transaction. Historical insider transactions for iPass go as follows:

  • 4-Week # shares bought: 25,000
  • 4-Week # shares sold: 130,249
  • 12-Week # shares bought: 55,000
  • 12-Week # shares sold: 130,249
  • 24-Week # shares bought: 100,000
  • 24-Week # shares sold: 130,249

The average volume for iPass has been 150,400 shares per day over the past 30 days. iPass has a market cap of $75.6 million and is part of the technology sector and telecommunications industry. Shares are up 26% year-to-date as of the close of trading on Thursday.

iPass Inc. provides Wi-Fi network that enables Wi-Fi access on various mobile devices in the United States and internationally. Currently, there is 1 analyst who rates iPass a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPAS - FREE

TheStreet Quant Ratings rates iPass as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full iPass Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Synchronoss Technologies (SNCR) - FREE Research Report

Rosenberger Karen, who is EVP & Chief Financial Officer at Synchronoss Technologies, sold 83 shares at $35.30 on May 26, 2016. Following this transaction, the EVP & Chief Financial Officer owned 45,057 shares meaning that the stake was reduced by 0.18% with the 83-share transaction.

The shares most recently traded at $35.56, up $0.26, or 0.73% since the insider transaction. Historical insider transactions for Synchronoss Technologies go as follows:

  • 4-Week # shares sold: 13,000
  • 12-Week # shares sold: 69,073
  • 24-Week # shares sold: 198,652

The average volume for Synchronoss Technologies has been 371,100 shares per day over the past 30 days. Synchronoss Technologies has a market cap of $1.6 billion and is part of the technology sector and computer software & services industry. Shares are up 0.97% year-to-date as of the close of trading on Thursday.

Synchronoss Technologies, Inc. provides cloud solutions and software-based activation for mobile carriers, enterprises, retailers, and original equipment manufacturers (OEMs) worldwide. The company has a P/E ratio of 73.5. Currently, there are 5 analysts who rate Synchronoss Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNCR - FREE

TheStreet Quant Ratings rates Synchronoss Technologies as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Synchronoss Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.